Public Release: 

Gene-edited stem cells show promise against HIV in non-human primates

Edited cells reduce size of 'viral reservoirs' that could reactivate to produce more virus copies

PLOS

IMAGE

IMAGE: Most strains of HIV use the CCR5 gene to enter host cells. Our study shows that editing CCR5 leads to a reduction in the number of infected cells throughout the... view more 

Credit: Grace Choi

Gene editing of bone marrow stem cells in pigtail macaques infected with simian/human immunodeficiency virus (SHIV) significantly reduces the size of dormant "viral reservoirs" that pose a risk of reactivation. Christopher Peterson of the Fred Hutchinson Cancer Research Center in Seattle, WA, and colleagues present these findings in PLOS Pathogens.

In 2007, HIV-positive Timothy Brown, also known as the Berlin Patient, received a bone marrow stem cell transplant to treat his leukemia. The procedure eliminated HIV from his system, likely facilitated by a mutation in the gene CCR5 in the donor cells that made them resistant to HIV. However, it is rare to find matching donors with CCR5 mutations, and transplant is considered too dangerous for otherwise healthy HIV-positive patients, due to risk of donor cells attacking patients' cells.

To address this challenge, Peterson and colleagues are exploring the use of gene editing techniques to introduce the CCR5 mutation into a patient's own stem cells. In previous work, they demonstrated the ability to safely remove bone marrow stem cells from a healthy macaque, edit the CCR5 gene, and transplant the cells back into the macaque, where the CCR5-mutant cells successfully multiplied.

Now, the research team has performed the same technique in macaques infected with simian/human immunodeficiency virus (SHIV) and receiving antiretroviral therapy, making them analogous to HIV-infected people undergoing treatment to keep their HIV levels low. The scientists found that, after transplant, the CCR5 gene-edited cells were able to multiply in the macaques, giving rise to white blood cells that also had the mutation and were therefore resistant to SHIV.

Tissue analysis of the macaques detected edited cells in viral reservoirs--collections of infected cells that have been hijacked by SHIV to produce more copies of the virus, but are currently in a dormant state. The edited cells appeared to reduce the size of these reservoirs, which is notable because viral reservoirs may reactivate to produce more SHIV at any time, and antiretroviral therapies have no effect on them.

Over time, about 4 percent of each macaque's white blood cells consisted of cells with the CCR5 edit--too low a percentage to induce SHIV remission without also continuing antiretroviral therapy. The research team is now working to increase the efficiency of their gene-editing technique in order to raise this percentage. With better efficiency and in combination with other strategies, gene editing could one day help fight HIV in people.

###

In your coverage please use this URL to provide access to the freely available article in PLOS Pathogens: http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006956

Citation: Peterson CW, Wang J, Deleage C, Reddy S, Kaur J, Polacino P, et al. (2018) Differential impact of transplantation on peripheral and tissue-associated viral reservoirs: Implications for HIV gene therapy. PLoS Pathog 14(4): e1006956. https://doi.org/10.1371/journal.ppat.1006956

Image Credit: Grace Choi

Funding: This study was supported by grants from the National Institutes of Health, National Institute of Allergy and Infectious Diseases (U19 AI096111 and UM1 AI126623 to HPK and KRJ); the National Heart, Lung, and Blood Institute (R01 HL116217 and U19 HL129902 to HPK); and the Office of Research Infrastructure Programs (ORIP) (P51 0D010425 to SLH). HPK is a Markey Molecular Medicine Investigator and received support as the inaugural recipient of the José Carreras/E. Donnall Thomas Endowed Chair for Cancer Research and the Fred Hutch Endowed Chair for Cell and Gene Therapy. This project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. NIH Further information on the NIH grants listed can be accessed via NIH RePORT: https://projectreporter.nih.gov/reporter.cfm

Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: AR and MCH are current full-time employees, and JW is a former full-time employee of Sangamo Therapeutics.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.